Value of circulating GPC3 m RNA in detecting patient with hepatocellular carcinoma /
Huda Ali Moustafa Karmani
Value of circulating GPC3 m RNA in detecting patient with hepatocellular carcinoma / دور الحامض الريبوزومى الرسولى للجليبكان 3 فى الكشف عن المرضى المصابين بسرطان الكب Huda Ali Moustafa Karmani ; Supervised Nehad Ahmad Mosaad , Ashraf Omar Abdelaziz , Yassmin Taha Elshewey - Cairo : Huda Ali Moustafa Karmani , 2016 - 133 P. ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Aim: Is to test the clinical performance of GLYPICAN 3 gene expression as a new and specific diagnostic molecular marker in hepatocellular carcinoma by real time PCR and its protein level in serum by ELISA. The serum GPC3 protein and GPC 3 m-RNA level were measured in 30 patients with HCC and 25 patients with cirrhotic liver disease (CLD) and 25 normal healthy control by RT-PCR and by ELISA. The median values of GPC3 m-RNA by RT-PCR in patients with HCC and with CLD and in control group were 2.68ng/mL, 0.843ng/mL and 0.2ng/ml respectively. We found There was no statistically significant elevation between the HCC group as compared to the CLD groups with (p = 0.407), while both groups were significantly higher than control group (p = 0.001). The median values of serum GPC3 protein by ELISA in patients with HCC and with CLD and in control group were 2.9ng/mL, 2.4ng/ml and 2.1ng/mL, respectively. We found that there was no statistically significant difference between the HCC and the CLD groups with (p = 0.488), while both groups were significantly higher than control group (p = 0.004). The median values of serum AFP by ELISA in patients with HCC and with CLD and in control groups were 171.0 ng/mL,13ng/ml and 2.3ng/mL, respectively. We found that. There was statistically significant difference between the HCC and the CLD groups with (p=0.000). And both of them were statistcally higher than the control group p = 0.000
ELISA Glypican-3 Hepatocellular carcinoma
Value of circulating GPC3 m RNA in detecting patient with hepatocellular carcinoma / دور الحامض الريبوزومى الرسولى للجليبكان 3 فى الكشف عن المرضى المصابين بسرطان الكب Huda Ali Moustafa Karmani ; Supervised Nehad Ahmad Mosaad , Ashraf Omar Abdelaziz , Yassmin Taha Elshewey - Cairo : Huda Ali Moustafa Karmani , 2016 - 133 P. ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Aim: Is to test the clinical performance of GLYPICAN 3 gene expression as a new and specific diagnostic molecular marker in hepatocellular carcinoma by real time PCR and its protein level in serum by ELISA. The serum GPC3 protein and GPC 3 m-RNA level were measured in 30 patients with HCC and 25 patients with cirrhotic liver disease (CLD) and 25 normal healthy control by RT-PCR and by ELISA. The median values of GPC3 m-RNA by RT-PCR in patients with HCC and with CLD and in control group were 2.68ng/mL, 0.843ng/mL and 0.2ng/ml respectively. We found There was no statistically significant elevation between the HCC group as compared to the CLD groups with (p = 0.407), while both groups were significantly higher than control group (p = 0.001). The median values of serum GPC3 protein by ELISA in patients with HCC and with CLD and in control group were 2.9ng/mL, 2.4ng/ml and 2.1ng/mL, respectively. We found that there was no statistically significant difference between the HCC and the CLD groups with (p = 0.488), while both groups were significantly higher than control group (p = 0.004). The median values of serum AFP by ELISA in patients with HCC and with CLD and in control groups were 171.0 ng/mL,13ng/ml and 2.3ng/mL, respectively. We found that. There was statistically significant difference between the HCC and the CLD groups with (p=0.000). And both of them were statistcally higher than the control group p = 0.000
ELISA Glypican-3 Hepatocellular carcinoma